Myocardial fatty acid utilization as a determinant of cardiac efficiency and function

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 379-389

  Jaswal, Jagdip S ^a   Ussher, John R ^b   Lopaschuk, Gary D ^b  

^a Perinatal Research Centre   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiac efficiency; Cardiac function; Fatty acid oxidation; Glucose oxidation; Ionic homeostasis; Oxygen consumption

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A; ADENOSINE TRIPHOSPHATE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DICHLOROACETIC ACID; ETOMOXIR; INSULIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RANOLAZINE; TRIMETAZIDINE; UNCOUPLING PROTEIN;

CARDIOVASCULAR RESPONSE; CELL METABOLISM; DRUG MECHANISM; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLYCOGEN SYNTHESIS; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HUMAN; ISCHEMIA; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

EID: 67249141420     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.18     Document Type: Review

References (99)

1. Bing RJ, Hammond MM, Handelsman JC et al.: The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am. Heart J. 38, 1-24 (1949).
2. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093-1129 (2005).
3. Suga H: Ventricular energetics. Physiol. Rev. 70, 247-277 (1990).
4. Suga H: Cardiac energetics: from E(max) to pressure-volume area. Clin. Exp. Pharmacol. Physiol. 30, 580-585 (2003).
5. Knaapen P, Germans T, Knuuti J et al.: Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 115, 918-927 (2007).
6. 2 framework. Acta Physiol. 190, 171-175 (2007).
7. Aasum E, Hafstad AD, Severson DL, Larsen TS: Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52, 434-441 (2003).
8. Mazumder PK, O'Neill BT, Roberts MW et al.: Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ ob mouse hearts. Diabetes 53, 2366-2374 (2004).
9. Carley AN, Severson DL: Fatty acid metabolism is enhanced in Type 2 diabetic hearts. Biochim. Biophys. Acta 1734, 112-126 (2005).
10. Carroll R, Carley AN, Dyck JR, Severson DL: Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am. J. Physiol. Endocrinol. Metab. 288, E900-E906 (2005).
11. Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC: Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am. J. Physiol. Heart Circ. Physiol. 288, H2102-H2110 (2005).
12. Peterson LR, Herrero P, Schechtman KB et al.: Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109, 2191-2196 (2004).
13. Buchanan J, Mazumder PK, Hu P et al.: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146, 5341-5349 (2005).
14. Aasum E, Belke DD, Severson DL et al.: Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-α activator. Am. J. Physiol. Heart Circ. Physiol. 283, H949-H957 (2002).
15. Belke DD, Larsen TS, Gibbs EM, Severson DL: Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 279, E1104-E1113 (2000).
16. Suga H: Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am. J. Physiol. 236, H498-H505 (1979).
17. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R: Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail. Rev. 7, 187-203 (2002).
18. Hinkle PC: P/O ratios of mitochondrial oxidative phosphorylation. Biochim. Biophys. Acta 1706, 1-11 (2005).
19. Kadenbach B: Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta 1604, 77-94 (2003).
20. Nicholls DG, Bernson VS, Heaton GM: The identification of the component in the inner membrane of brown adipose tissue mitochondria responsible for regulating energy dissipation. Experientia Suppl. 32, 89-93 (1978).
21. Rousset S, Alves-Guerra MC, Mozo J et al.: The biology of mitochondrial uncoupling proteins. Diabetes 53(Suppl. 1), S130-S135 (2004).
22. Schrauwen P, Hesselink M: UCP2 and UCP3 in muscle controlling body metabolism. J. Exp. Biol. 205, 2275-2285 (2002).
23. Hidaka S, Kakuma T, Yoshimatsu H et al.: Streptozotocin treatment upregulates uncoupling protein 3 expression in the rat heart. Diabetes 48, 430-435 (1999).
24. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K: Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am. J. Physiol. Heart Circ. Physiol. 280, H977-H983 (2001).
25. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K: Uncoupling proteins in human heart. Lancet 364, 1786-1788 (2004).
26. Murray AJ, Cole MA, Lygate CA et al.: Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. J. Mol. Cell. Cardiol. 44, 694-700 (2008).
27. Boudina S, Sena S, Theobald H et al.: Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56, 2457-2466 (2007).
28. Boudina S, Sena S, O'Neill BT et al.: Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112, 2686-2695 (2005).
29. How OJ, Aasum E, Severson DL et al.: Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55, 466-473 (2006).
30. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E: Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from Type 2 diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 292, E1288-E1294 (2007).
31. Boudina S, Abel ED: Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21, 250-258 (2006).
32. Ricquier D, Bouillaud F: The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem. J. 345(Pt 2), 161-179 (2000).
33. Boss O, Hagen T, Lowell BB: Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes 49, 143-156 (2000).
34. Weigle DS, Selfridge LE, Schwartz MW et al.: Elevated free fatty acids induce uncoupling protein 3 expression in muscle: a potential explanation for the effect of fasting. Diabetes 47, 298-302 (1998).
35. Khalfallah Y, Fages S, Laville M, Langin D, Vidal H: Regulation of uncoupling protein-2 and uncoupling protein-3 mRNA expression during lipid infusion in human skeletal muscle and subcutaneous adipose tissue. Diabetes 49, 25-31 (2000).
36. Echtay KS, Murphy MP, Smith RA, Talbot DA, Brand MD: Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J. Biol. Chem. 277, 47129-47135 (2002).
37. Echtay KS, Roussel D, St-Pierre J et al.: Superoxide activates mitochondrial uncoupling proteins. Nature 415, 96-99 (2002).
38. Murphy MP, Echtay KS, Blaikie FH et al.: Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from α-phenyl-N-tert-butylnitrone. J. Biol. Chem. 278, 48534-48545 (2003).
39. Seifert EL, Bezaire V, Estey C, Harper ME: Essential role for uncoupling protein-3 in mitochondrial adaptation to fasting but not in fatty acid oxidation or fatty acid anion export. J. Biol. Chem. 283, 25124-25131 (2008).
40. Hunt MC, Alexson SE: The role acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog. Lipid Res. 41, 99-130 (2002).
41. Himms-Hagen J, Harper ME: Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp. Biol. Med. (Maywood) 226, 78-84 (2001).
42. Saddik M, Lopaschuk GD: Myocardial triglyceride turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J. Biol. Chem. 267, 3825-3831 (1992).
43. Myrmel T, Forsdahl K, Larsen TS: Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J. Mol. Cell. Cardiol. 24, 855-868 (1992).
44. Kourie JI: Interaction of reactive oxygen species with ion transport mechanisms. Am. J. Physiol. 275, C1-C24 (1998).
45. Bolli R, Marban E: Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 79, 609-634 (1999).
46. + regulation in cardiac myocytes. Cardiovasc. Res. 57, 897-912 (2003).
47. Blaustein MP, Lederer WJ: Sodium/calcium exchange: its physiological implications. Physiol. Rev. 79, 763-854 (1999).
48. 2+ overload and left ventricular mechanical dysfunction. J. Cardiovasc. Electrophysiol. 17(Suppl. 1), S141-S148 (2006).
49. Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD: High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J. Am. Coll. Cardiol. 39, 718-725 (2002).
50. Hool LC: What cardiologists should know about calcium ion channels and their regulation by reactive oxygen species. Heart Lung Circ. 16, 361-372 (2007).
51. Rowe GT, Manson NH, Caplan M, Hess ML: Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. Circ. Res. 53, 584-591 (1983).
52. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785-789 (1963).
53. Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14, 263-283 (1998).
54. Dennis SC, Gevers W, Opie LH: Protons in ischemia: where do they come from; where do they go to? J. Mol. Cell. Cardiol. 23, 1077-1086 (1991).
55. Robergs RA, Ghiasvand F, Parker D: Biochemistry of exercise-induced metabolic acidosis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R502-R516 (2004).
56. Lysiak W, Toth PP, Suelter CH, Bieber LL: Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J. Biol. Chem. 261, 13698-13703 (1986).
57. Ussher JR, Lopaschuk GD: The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc. Res. 79, 259-268 (2008).
58. Hafstad AD, Solevag GH, Severson DL, Larsen TS, Aasum E: Perfused hearts from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin. Am. J. Physiol. Heart Circ. Physiol. 290, H1763-H1769 (2006).
59. Schonekess BO, Allard MF, Henning SL, Wambolt RB, Lopaschuk GD: Contribution of glycogen and exogenous glucose to glucose metabolism during ischemia in the hypertrophied rat heart. Circ. Res. 81, 540-549 (1997).
60. Henning SL, Wambolt RB, Schonekess BO, Lopaschuk GD, Allard MF: Contribution of glycogen to aerobic myocardial glucose utilization. Circulation 93, 1549-1555 (1996).
61. Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61, 448-460 (2004).
62. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR: Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ. Res. 66, 546-553 (1990).
63. Leong HS, Grist M, Parsons H et al.: Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am. J. Physiol. Endocrinol. Metab. 282, E1039-E1045 (2002).
64. Jain M, Cui L, Brenner DA et al.: Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation 109, 898-903 (2004).
65. Jain M, Brenner DA, Cui L et al.: Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ. Res. 93, e9-e16 (2003).
66. Carley AN, Semeniuk LM, Shimoni Y et al.: Treatment of type 2 diabetic db/db mice with a novel PPARgγ agonist improves cardiac metabolism but not contractile function. Am. J. Physiol. Endocrinol. Metab. 286, E449-E455 (2004).
67. Golfman LS, Wilson CR, Sharma S et al.: Activation of PPARγ enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am. J. Physiol. Endocrinol. Metab. 289, E328-E336 (2005).
68. How OJ, Larsen TS, Hafstad AD et al.: Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch. Physiol. Biochem. 113, 211-220 (2007).
69. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K: Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51, 1110-1117 (2002)
70. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Malloy CR: Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol. 25, 469-472 (1995).
71. Lopaschuk GD, Wall SR, Olley PM, Davies NJ: Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ. Res. 63, 1036-1043 (1988).
72. Lee L, Campbell R, Scheuermann-Freestone M et al.: Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112, 3280-3288 (2005).
73. Schmidt-Schweda S, Holubarsch C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. 99, 27-35 (2000).
74. Lopaschuk GD, Rebeyka IM, Allard MF: Metabolic modulation: a means to mend a broken heart. Circulation 105, 140-142 (2002).
75. Dyck JR, Cheng JF, Stanley WC et al.: Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ. Res. 94, e78-e84 (2004).
76. Dyck JR, Hopkins TA, Bonnet S et al.: Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 114, 1721-1728 (2006).
77. Kantor PF, Lucien A, Kozak R, Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86, 580-588 (2000).
78. Lopaschuk GD, Barr R, Thomas PD, Dyck JR: Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93, e33-e37 (2003).
79. Fragasso G, Palloshi A, Puccetti P et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 48, 992-998 (2006).
80. Fragasso G, Perseghin G, De Cobelli F et al.: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur. Heart J. 27, 942-948 (2006).
81. Tuunanen H, Engblom E, Naum A et al.: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118, 1250-1258 (2008).
82. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93, 135-142 (1996).
83. Chaitman BR, Pepine CJ, Parker JO et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309-316 (2004).
84. Chaitman BR, Skettino SL, Parker JO et al.: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375-1382 (2004).
85. Rousseau MF, Pouleur H, Cocco G, Wolff AA: Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. 95, 311-316 (2005).
86. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol. 48, 566-575 (2006).
87. Timmis AD, Chaitman BR, Crager M: Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. 27, 42-48 (2006).
88. Peterson LR, Herrero P, McGill J et al.: Fatty acids and insulin modulate myocardial substrate metabolism in humans with Type 1 diabetes. Diabetes 57, 32-40 (2008).
89. Herrero P, Peterson LR, McGill JB et al.: Increased myocardial fatty acid metabolism in patients with Type 1 diabetes mellitus. J. Am. Coll. Cardiol. 47, 598-604 (2006).
90. Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 51, 93-102 (2008).
91. Haessler R, Davis RF, Wolff RA, Kozume K, Shangraw R, Van Winkle DM: Dichloroacetate reduces plasma lactate levels but does not reduce infarct size in rabbit myocardium. Shock 5, 66-71 (1996).
92. Mazer CD, Cason BA, Stanley WC et al.: Dichloroacetate stimulates carbohydrate metabolism but does not improve systolic function in ischemic pig heart. Am. J. Physiol. 268, H879-H885 (1995).
93. Wang P, Lloyd SG, Chatham JC: Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. Circulation 111, 2066-2072 (2005).
94. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF: Dichloroacetate improves postischemic function of hypertrophied rat hearts. J. Am. Coll. Cardiol. 36, 1378-1385 (2000).
95. Taniguchi M, Wilson C, Hunter CA et al.: Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am. J. Physiol. Heart Circ. Physiol. 280, H1762-H1769 (2001).
96. Gandhi M, Finegan BA, Clanachan AS: Role of glucose metabolism in the recovery of postischemic LV mechanical function: effects of insulin and other metabolic modulators. Am. J. Physiol. Heart Circ. Physiol. 294, H2576-H2586 (2008).
97. Liu B, Clanachan AS, Schulz R, Lopaschuk GD: Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ. Res. 79, 940-948 (1996).
98. Wargovich TJ, MacDonald RG, Hill JA et al.: Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am. J. Cardiol. 61, 65-70 (1988).
99. Folmes CD, Clanachan AS, Lopaschuk GD: Fatty acids attenuate insulin regulation of 5′-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ. Res. 99, 61-68 (2006).